Core Viewpoint - AI Technology Group Inc. has announced an agreement to acquire AVM Biotechnology Inc., which will result in AVM becoming a wholly owned subsidiary, pending customary closing conditions [1] Company Overview - AI Technology Group is a Nevada corporation that will be subject to ongoing SEC reporting requirements upon the effectiveness of its Form 10 [6] Acquisition Details - The acquisition involves a newly formed subsidiary of AI Technology Group merging with AVM Biotechnology, with plans to change the corporate name and ticker symbol post-closing [1] AVM Biotechnology Overview - AVM Biotechnology is commercializing AVM0703, a small-molecule drug designed to treat various cancers through a one-hour outpatient infusion that reactivates the body's immune system [2] - AVM0703 is currently in Phase 2 human trials for relapsed/refractory non-Hodgkin lymphoma and has applications for autoimmune diseases and infectious diseases [2][3] Clinical Development - A total of 90 patients have been treated in the Phase 1b/2 clinical trial, with no cumulative toxicity observed across multiple infusions [3] - The drug has shown no safety signals in 90 subjects treated, even with repeat dosing up to 19 cycles [2][3] Leadership and Expertise - AVM is led by Dr. Theresa Deisher, an expert in stem-cell and immunology with over 30 years of experience in drug development and a significant patent portfolio [4] Financing - AI Technology Group is conducting a private financing round aiming to raise at least $14 million at a price of $2.50 per share to support AVM's clinical development [5]